Iversun represents a significant advancement in antiparasitic therapy, offering a targeted and highly effective solution for a range of parasitic infections. Formulated with ivermectin, a medication recognized by the World Health Organization as an essential medicine, Iversun works by binding to glutamate-gated chloride ion channels in invertebrate nerve and muscle cells. This action increases cell membrane permeability to chloride ions, resulting in hyperpolarization of the cells, subsequent paralysis, and death of the parasites. Its broad-spectrum efficacy, combined with a well-documented safety profile when used as directed, makes it a cornerstone in both clinical and public health settings for combating neglected tropical diseases and common parasitic infestations.

Features

• Contains ivermectin as the active pharmaceutical ingredient (API)
• Available in multiple formulations: 3 mg and 6 mg scored tablets for precise dosing
• Manufactured in cGMP-certified facilities ensuring pharmaceutical-grade purity and consistency
• High bioavailability and a predictable pharmacokinetic profile
• Selective activity against parasites with a high margin of safety for human hosts
• Long half-life, allowing for sustained antiparasitic effect

Benefits

• Achieves rapid and effective eradication of target parasitic organisms, alleviating clinical symptoms and preventing disease progression.
• Contributes to the reduction of parasite transmission within communities, supporting broader public health eradication programs.
• The single-dose regimen for many indications enhances patient compliance and simplifies treatment protocols in both outpatient and mass drug administration settings.
• Its mechanism of action provides a high therapeutic index, minimizing the risk of adverse effects in the human host when administered correctly.
• Proven efficacy against a spectrum of parasites reduces the need for multiple, different medications, streamlining treatment.
• Helps prevent long-term complications associated with chronic parasitic infections, such as blindness (in onchocerciasis) and debilitating lymphatic damage (in lymphatic filariasis).

Common use

Iversun (ivermectin) is indicated for the treatment of specific parasitic infestations. Its primary uses include the treatment of strongyloidiasis of the intestinal tract, caused by the nematode Strongyloides stercoralis. It is also a critical agent in the treatment of onchocerciasis (river blindness), caused by the filarial worm Onchocerca volvulus. Furthermore, it is used in mass drug administration programs for the elimination of lymphatic filariasis (elephantiasis), often in combination with other agents, in regions where it is endemic. Off-label, it is sometimes used under medical supervision for other ectoparasitic conditions such as scabies and head lice.

Dosage and direction

Dosage is strictly based on body weight to ensure efficacy and safety. The standard dose is 150-200 micrograms per kilogram of body weight. For the 3 mg tablet, this typically translates to approximately one tablet per 15-20 kg of body weight. Tablets should be taken orally with a full glass of water on an empty stomach (at least 1 hour before or 2 hours after a meal) to maximize absorption. Dosing may be repeated for certain conditions as determined by a healthcare provider. For mass treatment of onchocerciasis, dosing is often administered annually or semi-annually. It is imperative that dosing follows the precise calculation and schedule prescribed by a physician.

Precautions

A thorough medical history should be obtained prior to administration. Use with caution in patients with asthma or a severe allergic reaction to any component of the medication. Patients from regions endemic for Loa loa (African eye worm) must be screened prior to treatment, as ivermectin can cause serious encephalopathic reactions in individuals with high microfilarial loads. Patients should be advised that a temporary worsening of itching or a rash may occur in the days following treatment for onchocerciasis due to the death of microfilariae (Mazzotti reaction). The safety of Iversun in children weighing less than 15 kg has not been established.

Contraindications

Iversun is contraindicated in patients with a known hypersensitivity to ivermectin or any other ingredient in the formulation. It is not recommended for use during pregnancy unless the potential benefit justifies the potential risk to the fetus, due to insufficient safety data. It should not be administered to breastfeeding mothers unless explicitly advised by a physician, as ivermectin is excreted in human milk. Concurrent administration with other drugs that potentiate GABA-ergic activity (e.g., barbiturates, benzodiazepines, valproic acid) is contraindicated due to theoretical risk of enhanced CNS depression.

Possible side effect

While generally well-tolerated, some patients may experience side effects, which are often mild and transient. Common side effects include dizziness, pruritus (itching), skin rash, edema (swelling), particularly of the face and extremities, abdominal pain, nausea, diarrhea, and transient tachycardia (elevated heart rate). In the treatment of onchocerciasis, the Mazzotti reaction (fever, itching, tender lymph nodes, joint pain, hypotension) is a common and expected side effect due to the body’s reaction to dying parasites. Less frequently, patients may experience orthostatic hypotension, vertigo, and somnolence. Serious side effects are rare but require immediate medical attention.

Drug interaction

Iversun is primarily metabolized by the liver enzyme CYP3A4. Concomitant use with potent inhibitors of CYP3A4 (e.g., ketoconazole, itraconazole, ritonavir, clarithromycin) may increase ivermectin plasma concentrations. Conversely, inducers of CYP3A4 (e.g., rifampin, carbamazepine, phenytoin, St. John’s Wort) may decrease ivermectin plasma levels, potentially reducing its efficacy. As a substrate for P-glycoprotein, interactions with inhibitors of this transport protein are also possible. Caution is advised when administering with other medications that depress the central nervous system.

Missed dose

If a dose is missed, it should be taken as soon as it is remembered. However, if it is almost time for the next scheduled dose, the missed dose should be skipped, and the regular dosing schedule resumed. Patients should not take a double dose to make up for a missed one. For single-dose regimens common in parasitic treatment, consult the prescribing physician for guidance if the dose was missed entirely.

Overdose

Overdose with Iversun is associated with an extension of its pharmacological effects. Symptoms may include severe dizziness, nausea, vomiting, pupillary dilation, altered mental status, seizures, ataxia (loss of coordination), and profound hypotension. In cases of significant overdose, CNS depression including coma may occur. There is no specific antidote for ivermectin overdose. Management is supportive and symptomatic, including gastric lavage and activated charcoal if ingestion was recent, alongside maintaining a patent airway and adequate ventilation.

Storage

Store Iversun tablets at controlled room temperature, between 20°C to 25°C (68°F to 77°F). Excursions are permitted between 15°C and 30°C (59°F and 86°F). The medication must be kept in its original blister packaging or container to protect it from light and moisture. Always keep all medications out of the reach of children and pets. Do not use tablets that are beyond their expiration date or show signs of physical degradation.

Disclaimer

This information is for educational and informational purposes only and does not constitute medical advice. It is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or before starting any new treatment. Never disregard professional medical advice or delay in seeking it because of something you have read in this product description.

Reviews

• “As an infectious disease specialist working in a endemic zone, Iversun has been indispensable in our filariasis control program. Its efficacy and the simplicity of the single-dose regimen have dramatically improved our community health metrics.” – Dr. A. Sharma, MD
• “After a difficult case of chronic strongyloidiasis that was resistant to initial treatments, a course of Iversun finally cleared the infection. My energy levels returned to normal within weeks. The follow-up tests were negative.” – Patient M.T.
• “From a pharmacological standpoint, the consistency and quality of this branded ivermectin are superior to many generics we’ve tested. The scored tablets allow for accurate weight-based dosing, which is critical.” – Clinical Pharmacist Review
• “We used Iversun in a coordinated scabies outbreak management plan at a long-term care facility. The results were swift and effective, halting the outbreak with two treated doses. Minimal side effects were reported among the residents.” – Facility Director, RN